Nassim Usman Biography and Net Worth

Director of Gyre Therapeutics

Before joining Totus Medicines, Dr. Usman served as President, CEO and Board member at Catalyst Biosciences (NASDAQ:CBIO, now Gyre Therapeutics, NASDAQ:GYRE). Dr. Usman has an extensive background in C‑Suite management (CSO, COO, CEO and Principal Financial Officer), Board membership on and venture capital investing (Morgenthaler Ventures) in several private and public companies including Sirna Therapeutics (acquired by Merck) and Principia Biopharma (acquired by Sanofi). Dr. Usman currently serves on the Board of GYRE and the advisory boards of two private biotechnology companies. During his career, he has advanced several drugs into clinical development, executed multiple licensing deals, and raised capital through private and public financings. Dr. Usman received his B.Sc. and Ph.D. in Organic Chemistry from McGill University and completed a post-doctoral fellowship at MIT.

What is Nassim Usman's net worth?: The estimated net worth of Nassim Usman is at least $15,034.84 as of June 28th, 2024. Usman owns 1,636 shares of Gyre Therapeutics stock worth more than $15,035 as of April 24th. This net worth evaluation does not reflect any other assets that Usman may own. Learn More about Nassim Usman's net worth.
How do I contact Nassim Usman?: The corporate mailing address for Usman and other Gyre Therapeutics executives is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. Gyre Therapeutics can also be reached via phone at (619) 949-3681 and via email at investors@catbio.com. Learn More on Nassim Usman's contact information.
Has Nassim Usman been buying or selling shares of Gyre Therapeutics?: Nassim Usman has not been actively trading shares of Gyre Therapeutics in the last ninety days. Most recently, Nassim Usman sold 3,452 shares of the business's stock in a transaction on Friday, June 28th. The shares were sold at an average price of $12.00, for a transaction totalling $41,424.00. Following the completion of the sale, the director now directly owns 1,636 shares of the company's stock, valued at $19,632. Learn More on Nassim Usman's trading history.
Who are Gyre Therapeutics' active insiders?: Gyre Therapeutics' insider roster includes Songjiang Ma (President), and Nassim Usman (Director). Learn More on Gyre Therapeutics' active insiders.
Are insiders buying or selling shares of Gyre Therapeutics?: During the last year, insiders at the sold shares 25 times. They sold a total of 65,506 shares worth more than $799,621.30. The most recent insider tranaction occured on March, 19th when President Songjiang Ma sold 2,000 shares worth more than $20,260.00. Insiders at Gyre Therapeutics own 19.5% of the company. Learn More about insider trades at Gyre Therapeutics.
Information on this page was last updated on 3/19/2025.

Nassim Usman Insider Trading History at Gyre Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/28/2024	Sell	3,452	$12.00	$41,424.00	1,636
5/1/2024	Sell	20,000	$14.13	$282,600.00	1,636

Nassim Usman Buying and Selling Activity at Gyre Therapeutics

Gyre Therapeutics Company Overview

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Today's Range

Now: $9.19

$8.93

$9.48

50 Day Range

MA: $9.63

$6.41

$12.62

2 Week Range

Now: $9.19

$6.11

$19.00

Volume

105,491 shs

Average Volume

92,662 shs

Market Capitalization

$860.29 million

P/E Ratio

183.80

Dividend Yield

N/A

Beta

2.03